ArticleBMC cancer2026
Uncovering the mechanism of DCLK3 in colorectal cancer progression through WGCNA and machine learning.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract with high morbidity and mortality rates. Although doublecortin like kinase 3 (DCLK3) is upregulated in CRC and promotes disease progression, its specific mechanisms remain unclear.
methodsCore factors of CRC were identified through bioinformatics analysis, weighted gene co-expression network analysis (WGCNA), and machine learning algorithms. The expression level of DCLK3 and ELK1 were evaluated using bioinformatics databases (GSE142279, The Cancer Genome Atlas (TCGA)) and experimental validation (quantitative real-time PCR (qRT-PCR), Western blot). Functional assays (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, Transwell assay, wound healing assay, sphere formation assay, tube formation assay, in vivo model, hematoxylin and eosin staining (HE), and immunohistochemistry (IHC)) and mechanism studies (prediction via Genecards and JASPAR databases, dual-luciferase reporter assay, and chromatin immunoprecipitation (ChIP)) were performed to validate and explore the molecular mechanism of DCLK3 in CRC.
resultsBioinformatics analysis combined with WGCNA and machine learning algorithms identified DCLK3 as a core gene. DCLK3 was significantly upregulated in CRC, and its high expression was associated with poorer overall survival in patients. Knockdown of DCLK3 inhibited the proliferation of CRC cells, promoted apoptosis, and suppressed cell invasion, migration, cancer stemness, and angiogenesis. ETS like-1 protein (ELK1) promoted malignant phenotypes in CRC cells by transcriptionally activating DCLK3. Also, in vivo studies demonstrated that ELK1 activated DCLK3 to facilitate CRC tumor growth.
conclusionDCLK3, identified through bioinformatic analysis, promotes CRC progression via its transcriptional activation by the transcription factor ELK1, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.